{"name":"ACADIA PHARMS INC","slug":"acadia-pharms-inc","ticker":"","exchange":"","domain":"acadiapharms.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":900000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Nuplazid","genericName":"PIMAVANSERIN","slug":"pimavanserin","revenue":600000000,"yoyGrowth":0,"percentOfTotal":66.7},{"name":"Daybue","genericName":"TROFINETIDE","slug":"trofinetide","revenue":300000000,"yoyGrowth":0,"percentOfTotal":33.3}],"timeline":[{"date":"2016-01-01","label":"Nuplazid first approved","drug":"Nuplazid","drugSlug":"pimavanserin","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Daybue first approved","drug":"Daybue","drugSlug":"trofinetide","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":600000000,"percentOfTotal":66.7,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Nuplazid","genericName":"PIMAVANSERIN","slug":"pimavanserin","indication":"Parkinson's disease","status":"marketed","revenue":600000000}]},{"name":"Other","slug":"other","revenue":300000000,"percentOfTotal":33.3,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Daybue","genericName":"TROFINETIDE","slug":"trofinetide","indication":"Rett Syndrome Treatment","status":"marketed","revenue":300000000}]}],"pipeline":[{"name":"Nuplazid","genericName":"PIMAVANSERIN","slug":"pimavanserin","phase":"marketed","mechanism":"Nuplazid works by blocking the action of a specific chemical messenger in the brain called serotonin.","indications":["Parkinson's disease"],"catalyst":""},{"name":"Daybue","genericName":"TROFINETIDE","slug":"trofinetide","phase":"marketed","mechanism":"Daybue works by interacting with a specific target in the body to help manage symptoms of Rett syndrome.","indications":["Rett Syndrome Treatment"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}